**Amendment to the Claims:**

This listing of claims will replace all previous versions, and listings, of claims in this application.

**Listing of Claims:**

1. (currently amended) A compound ~~having the formula I~~ of the following formula



~~(I)~~



wherein:

Z is N;

Y is $CONR^5$, $NR^5CO$, $SO_2NR^5$, $NR^5SO_2$, $CH_2NR^5$, $NR^5CONR^5$, $CH_2CO$, CO or $CH_2O$;

X is N;

P is phenyl;

Q is $C_{1-6}$alkyl~~, $C_{2-6}$alkenyl or $C_{2-6}$alkynyl~~;

R is $C_{0-6}$alkyl$(SO_2)NR^1R^2$;

~~$R^1$ and $R^2$ are independently selected from hydrogen, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylheterocycloalkyl, $C_{1-6}$alkyl$NR^6R^7$, $C_{0-6}$alkylaryl and $C_{0-6}$alkylheteroaryl, wherein any $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylheterocycloalkyl, $C_{0-6}$alkylaryl, $C_{0-6}$alkylheteroaryl may be substituted by one or more A;~~

$R^1$ and $R^2$ [[may]] together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

~~$R^3$ is independently selected from halogen, nitro, CHO, $C_{0-6}$alkylCN, $OC_{1-6}$alkylCN, $C_{0-6}$alkylOR$^6$, $OC_{1-6}$alkylOR$^6$, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, $C_{0-6}$alkylNR$^6$R$^7$, $OC_{1-6}$alkylNR$^6$R$^7$, $OC_{1-6}$alkylO$C_{1-6}$alkylNR$^6$R$^7$, NR$^6$OR$^7$, $C_{0-6}$alkylCO$_2$R$^6$, $OC_{1-6}$alkylCO$_2$R$^6$, $C_{0-6}$alkylCONR$^6$R$^7$, $OC_{1-6}$alkylCONR$^6$R$^7$, $OC_{1-6}$alkylNR$^6$(CO)R$^7$, $C_{0-6}$alkylNR$^6$(CO)R$^7$, O(CO)NR$^6$R$^7$, NR$^6$(CO)OR$^7$, NR$^6$(CO)NR$^6$R$^7$, O(CO)OR$^6$, O(CO)R$^6$, $C_{0-6}$alkylCOR$^6$, $OC_{1-6}$alkylCOR$^6$, NR$^6$(CO)(CO)R$^6$, NR$^6$(CO)(CO)NR$^6$R$^7$, SR$^6$, $C_{0-6}$alkyl(SO$_2$)NR$^6$R$^7$, $OC_{1-6}$alkylNR$^6$(SO$_2$)R$^7$, $OC_{0-6}$alkyl(SO$_2$)NR$^6$R$^7$, $C_{0-6}$alkyl(SO)NR$^6$R$^7$, $OC_{1-6}$alkyl(SO)NR$^6$R$^7$, SO$_3$R$^6$, $C_{0-6}$alkylNR$^6$(SO$_2$)NR$^6$R$^7$, $C_{0-6}$alkylNR$^6$(SO)R$^7$, $OC_{1-6}$alkylNR$^6$(SO)R$^7$, $OC_{0-6}$alkylSO$_2$R$^6$, $C_{0-6}$alkylSO$_2$R$^6$, $C_{0-6}$alkylSOR$^6$, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylaryl and $C_{0-6}$alkylheteroaryl, wherein any $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylaryl and $C_{0-6}$alkylheteroaryl may be optionally substituted by one or more A;~~

$R^4$ is independently selected from ~~halogen, nitro, CHO, CN, $OC_{1-6}$alkylCN, OR$^6$, $OC_{1-6}$alkylOR$^6$, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, NR$^6$R$^7$, $OC_{1-6}$alkylNR$^6$R$^7$, NR$^6$OR$^7$, CO$_2$R$^6$, $OC_{1-6}$alkylCO$_2$R$^6$, CONR$^6$R$^7$, $OC_{1-6}$alkylCONR$^6$R$^7$, $OC_{1-6}$alkylNR$^6$(CO)R$^7$, NR$^6$(CO)R$^7$, O(CO)NR$^6$R$^7$, NR$^6$(CO)OR$^7$, NR$^6$(CO)NR$^6$R$^7$, O(CO)OR$^6$, O(CO)R$^6$, COR$^6$, $OC_{1-6}$alkylCOR$^6$, NR$^6$(CO)(CO)R$^6$, NR$^6$(CO)(CO)NR$^6$R$^7$, SR$^6$, (SO$_2$)NR$^6$R$^7$, $OC_{1-6}$alkylNR$^6$(SO$_2$)R$^7$, $OC_{0-6}$alkyl(SO$_2$)NR$^6$R$^7$, (SO)NR$^6$R$^7$, $OC_{1-6}$alkyl(SO)NR$^6$R$^7$, SO$_3$R$^6$, NR$^6$(SO$_2$)NR$^6$R$^7$, NR$^6$(SO)R$^7$, $OC_{1-6}$alkylNR$^6$(SO)R$^7$, $OC_{0-6}$alkylSO$_2$R$^6$, SO$_2$R$^6$, SOR$^6$, $C_{3-6}$cycloalkyl~~, CN, OR$^6$, CONR$^6$R$^7$, NR$^6$COR$^7$, (SO)NR$^6$R$^7$, SO$_2$R$^6$, phenyl, a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms independently selected from N, O, or S, or a 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O, or S which heterocyclic group may be saturated or unsaturated, and said phenyl ring or 5 or 6 membered heteroaromatic ring or 5 or 6 membered heterocyclic ring ~~may optionally be fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing atoms independently~~

~~selected from C, N, O or S wherein any $C_{3-6}$cycloalkyl, phenyl, 5 or 6 membered heteroaromatic ring with one or two heteroatoms selected independently from N, O, or S or a 5 or 6 membered heterocyclic containing one or two heteroatoms selected independently from N, O, or S;~~ may be optionally be substituted by one or more A;

~~m is 0;~~

n is [[0,]] 1~~, 2, 3 or 4~~;

$R^5$ is hydrogen or $C_{1-6}$alkyl;

$R^6$ and $R^7$ are independently selected from hydrogen, or $C_{1-6}$alkyl~~, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylaryl, $C_{0-6}$alkylheteroaryl and $C_{1-6}$alkyl$NR^8R^9$~~;

~~$R^6$ and $R^7$ may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A and wherein a $CH_2$ group may optionally be replaced by a CO group;~~

~~$R^8$ and $R^9$ are independently selected from hydrogen, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylaryl and $C_{0-6}$alkylheteroaryl;~~

~~$R^8$ and $R^9$ may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;~~

~~$R^{10}$ is hydrogen, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylaryl, $C_{0-6}$alkylheteroaryl or $C_{1-6}$alkyl$NR^8R^9$;~~

~~$R^{11}$ is $C_{1-6}$alkyl$NR^8R^9$;~~

~~$R^{10}$ and $R^{11}$ may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;~~

~~$R^{12}$ is a 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A; wherein any $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylheterocycloalkyl, $C_{0-6}$alkylaryl, $C_{0-6}$alkylheteroaryl defined under $R^5$ to $R^{12}$ may be substituted by one or more A;~~

A is oxo (=O), nitro, $OR^6$ or $C_{1-6}$alkyl ~~halo, oxo (=O), nitro, CHO, CN, $OR^6$, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, $C_{0-6}$alkyl$NR^6R^7$, $OC_{1-6}$alkyl$NR^6R^7$, $CO_2R^8$,~~

~~$CONR^6R^7$, $NR^6(CO)R^6$, $O(CO)R^6$, $COR^6$, $SR^6$, $(SO_2)NR^6R^7$, $(SO)NR^6R^7$, $SO_3R^6$, $SO_2R^6$ or $SOR^6$~~;

as a free base or a pharmaceutically acceptable ~~salt, solvate or solvate of a salt~~ thereof.

Claim 2 (cancelled).

3. (previously presented) A compound according to claim 1, wherein $R^1$ and $R^2$ in $C_{0-6}alkyl(SO_2)NR^1R^2$ together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S.

4. (original) A compound according to claim 3, wherein said heterocyclic ring comprises one or more N heteroatoms and said heterocyclic ring is optionally substituted by A, preferably a $C_{1-6}alkyl$.

5. (previously presented) A compound according to any one of claims 1, 3 or 4, wherein Y is $CONR^5$; $R^5$ is hydrogen; Q is $C_{1-6}alkyl$; $R^4$ is selected from: phenyl, 5 or 6 membered heteroaromatic ring containing one or more heteroatoms independently selected from N, O, or S or a 5 or 6 membered heterocyclic ring containing one or two heteroatoms selected independently from N, O, or S which heterocyclic group may be saturated or unsaturated, CN, $OR^6$, $SO_2R^6$, $NR^6(CO)R^7$, $(SO_2)NR^6R^7$, and $CONR^6R^7$; and n is 1; said phenyl or 5 or 6 membered heterocyclic ring optionally substituted by A.

6. (original) A compound according to claim 5, wherein A is selected from $OR^6$, $C_{1-6}alkyl$, oxo (=O) and nitro; and $R^6$ and/or $R^7$ is selected from $C_{1-6}alkyl$ and hydrogen.

7. (currently amended) A compound which is

3-Amino-*N*-(2-cyanoethyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

3-Amino-*N*-(3-amino-3-oxopropyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

3-Amino-*N*-(2-nitrobenzyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

3-Amino-*N*-(2-methoxybenzyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

3-Amino-*N*-(3-morpholin-4-ylpropyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

3-Amino-*N*-[3-(4-methylpiperazin-1-yl)propyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof;

3-Amino-*N*-(2-morpholin-4-ylethyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-[2-(1*H*-imidazol-4-yl)ethyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-[3-(1*H*-imidazol-1-yl)propyl]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride;

3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-(2-thien-2-ylethyl)pyrazine-2-carboxamide hydrochloride;

3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-(thien-2-ylmethyl)pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-(2-methoxyethyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-(3-methoxypropyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-(cyanomethyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide dihydrochloride;

3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(1*H*-pyrrol-1-yl)ethyl]-2-pyrazinecarboxamide hydrochloride;
3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(methylsulfonyl)ethyl]-2-pyrazinecarboxamide hydrochloride;
*N*-[2-(Acetylamino)ethyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;
3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[2-(2-oxo-1-imidazolidinyl)ethyl]-2-pyrazinecarboxamide hydrochloride;
3-Amino-*N*-[2-(aminosulfonyl)ethyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;
or as a free base or an alternative pharmaceutically acceptable ~~salt, solvate or solvate of a~~ salt thereof.

8. (previously presented) A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound according to any one of claims 1 or 7 in association with pharmaceutically acceptable carriers or diluents.

Claims 9 to 16. (Cancelled)

17. (withdrawn) A method of prevention and/or treatment of conditions associated with glycogen synthase kinase-3, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula **I** as defined in any one of claims 1 or 7.

18. (withdrawn) A method of prevention and/or treatment of dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex

of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula **I** as defined in any one of claims 1 or 7.

19. (withdrawn) The method according to claim 18, wherein the prevention and/or treatment is for Alzheimer's Disease.

20. (withdrawn) A method of prevention and/or treatment of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalitic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss and contraceptive medication, Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders,
comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula **I** as defined in any one of claims 1 or 7.

21. (withdrawn) The method according to claim 18, wherein the prevention and/or treatment is of Type I or Type II diabetes, diabetic neuropathy or diabetes related disorders.

22. (withdrawn) A method of prevention and/or treatment of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairement No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic alopecia, comprising administering to a

mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula **I** as defined in any one of claims 1 or 7.

23. (withdrawn) A process for the preparation of a compound of formula **I** according to claim 1, wherein Y, X, Z, P, Q, R, $R^1$, $R^2$, $R^3$, $R^4$, $R^5$, $R^6$, $R^7$, $R^8$, $R^9$, $R^{10}$, $R^{11}$, $R^{12}$, A, m and n are defined as in formula **I**, comprising of de-halogen coupling of a compound of formula **IV** with an appropriate aryl species;




**(IV)** **(I)**

to give a compound of formula **I**.

24. (withdrawn) A process for the preparation of a compound of formula **I** according to claim 1, wherein Y, X, Z, P, Q, R, $R^1$, $R^2$, $R^3$, $R^4$, $R^5$, $R^6$, $R^7$, $R^8$, $R^9$, $R^{10}$, $R^{11}$, $R^{12}$, A, m and n are defined as in formula **I**, comprising reacting of a compound of formula **XXII**:




**(XXII)** **(I)**

wherein the reaction is being performed by activation of a compound of formula **XXII** by treatment with a coupling agent or with an acyl halide reagent followed by treatment with the appropriate amine, followed by cleavage of the solid phase moiety by treatment with an suitable acid in a suitable solvent, and where the reaction temperature is between 0 °C and reflux, to give a compound of formula **I**.

25 and 26. (cancelled)

27. (withdrawn) A compound which is
4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid;
4-[(4-Methylpiperazin-1-yl)sulfonyl]phenylboronic acid;
as a free base or a salt, solvate or solvate of a salt thereof.

28. (withdrawn) A compound of formula **IV**




**(IV)**

wherein
Y is $CONR^5$, $NR^5CO$, $SO_2NR^5$, $NR^5SO_2$, $CH_2NR^5$ $NR^5CONR^5$, $CH_2CO$, CO or $CH_2O$;
X is CH or N;
Z is N;
Q is $C_{1-6}$alkyl, $C_{2-6}$alkenyl or $C_{2-6}$alkynyl;
$R^4$ is independently selected from halogen, nitro, CHO, CN, $OC_{1-6}$alkylCN, $OR^6$, $OC_{1-6}$alkyl$OR^6$, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, $NR^6R^7$, $OC_{1-6}$alkyl$NR^6R^7$, $NR^6OR^7$, $CO_2R^6$, $OC_{1-6}$alkyl$CO_2R^6$, $CONR^6R^7$,

$OC_{1-6}alkylCONR^6R^7$, $OC_{1-6}alkylNR^6(CO)R^7$, $NR^6(CO)R^7$, $O(CO)NR^6R^7$, $NR^6(CO)OR^7$, $NR^6(CO)NR^6R^7$, $O(CO)OR^6$, $O(CO)R^6$, $COR^6$, $OC_{1-6}alkylCOR^6$, $NR^6(CO)(CO)R^6$, $NR^6(CO)(CO)NR^6R^7$, $SR^6$, $(SO_2)NR^6R^7$, $OC_{1-6}alkylNR^6(SO_2)R^7$, $OC_{0-6}alkyl(SO_2)NR^6R^7$, $(SO)NR^6R^7$, $OC_{1-6}alkyl(SO)NR^6R^7$, $SO_3R^6$, $NR^6(SO_2)NR^6R^7$, $NR^6(SO)R^7$, $OC_{1-6}alkylNR^6(SO)R^7$, $OC_{0-6}alkylSO_2R^6$, $SO_2R^6$, $SOR^6$, $C_{3-6}$cycloalkyl, phenyl, a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms independently selected from N, O, or S, or a 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O, or S which heterocyclic group may be saturated or unsaturated, and said phenyl ring or 5 or 6 membered heteroaromatic ring or 5 or 6 membered heterocyclic ring may optionally be fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing atoms independently selected from C, N, O or S wherein any $C_{3-6}$cycloalkyl, phenyl, 5 or 6 membered heteroaromatic ring with one or two heteroatoms selected independently from N, O, or S or a 5 or 6 membered heterocyclic ring containing one or two heteroatoms selected independently from N, O, or S; may be optionally be substituted by one or more A;

$R^5$ is hydrogen or $C_{1-6}$alkyl

$R^6$ and $R^7$ are independently selected from hydrogen, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}alkylC_{3-6}$cycloalkyl, $C_{0-6}$alkylaryl, $C_{0-6}$alkylheteroaryl and $C_{1-6}alkylNR^8R^9$;

$R^6$ and $R^7$ may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A and wherein a $CH_2$ group may optionally be replaced by a CO group;

$R^8$ and $R^9$ are independently selected from hydrogen, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}alkylC_{3-6}$cycloalkyl, $C_{0-6}$alkylaryl and $C_{0-6}$alkylheteroaryl;

$R^8$ and $R^9$ may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

Hal is halogen;

n is 0, 1, 2, 3 or 4;

A is halogen, oxo (=O), nitro, CHO, CN, $OR^6$, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}alkylC_{3-6}$cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy,

difluoromethoxy, trifluoromethoxy, $C_{0-6}$alkyl$NR^6R^7$, $OC_{1-6}$alkyl$NR^6R^7$, $CO_2R^8$, $CONR^6R^7$, $NR^6(CO)R^6$, $O(CO)R^6$, $COR^6$, $SR^6$, $(SO_2)NR^6R^7$, $(SO)NR^6R^7$, $SO_3R^6$, $SO_2R^6$ or $SOR^6$;
as a free base or a salt, solvate or solvate of a salt thereof.

29. (withdrawn) A compound according to claim 28, wherein
Y is $CONR^5$;
X is N;
Q is $C_{1-6}$alkyl;
$R^4$ is independently selected from CN, $OR^6$, a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms independently selected from N, O, or S, or a 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O, or S which heterocyclic group may be saturated or unsaturated, wherein any 5 or 6 membered heterocyclic ring containing one or two heteroatoms selected independently from N, O, or S; may be optionally be substituted by A;
$R^5$ is hydrogen;
$R^6$ is, $C_{1-6}$alkyl;
n is 1;
A is oxo (=O);
as a free base or a salt, solvate or solvate of a salt thereof.

30. (withdrawn) A compound which is
3-Amino-6-bromo-*N*-(2-morpholin-4-ylethyl)pyrazine-2-carboxamide;
3-Amino-6-bromo-*N*-[2-(1*H*-imidazol-4-yl)ethyl]pyrazine-2-carboxamide;
3-Amino-6-bromo-*N*-[3-(1*H*-imidazol-1-yl)propyl]pyrazine-2-carboxamide;
3-Amino-6-bromo-*N*-(2-thien-2-ylethyl)pyrazine-2-carboxamide;
3-Amino-6-bromo-*N*-(thien-2-ylmethyl)pyrazine-2-carboxamide;
3-Amino-6-bromo-*N*-(2-methoxyethyl)pyrazine-2-carboxamide;
3-Amino-6-bromo-*N*-(3-methoxypropyl)pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]pyrazine-2-carboxamide;

3-Amino-6-bromo-*N*-(cyanomethyl)pyrazine-2-carboxamide;

as a free base or a salt, solvate or solvate of a salt thereof.

31. (withdrawn) A compound of formula **XXII**




**(XXII)**

wherein:

Z is N;

X is CH or N;

P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S and said phenyl ring or 5 or 6 membered heteroaromatic ring may optionally be fused with a 5 or 6 membered saturated, partially saturated or unsaturated ring containing atoms independently selected from C, N, O or S;

R is CHO, fluoromethoxy, difluoromethoxy, trifluoromethoxy, $C_{0-6}$alkyl$(SO_2)NR^1R^2$, $OC_{0-6}$alkyl$(SO_2)NR^1R^2$, $OC_{1-6}$alkyl$(SO)NR^1R^2$, $C_{1-6}$alkyl$(SO)NR^1R^2$, $C_{0-6}$alkyl$NR^1(SO)R^2$, $OC_{1-6}$alkyl$NR^1(SO)R^2$, $C_{0-6}$alkyl$NR^1(SO_2)NR^1R^2$, $OC_{1-6}$alkyl$NR^1(SO_2)R^2$, $C_{0-6}$alkyl$(SO_2)C_{1-6}$alkyl$NR^1R^2$, $OC_{0-6}$alkyl$(SO_2)C_{1-6}$alkyl$NR^1R^2$, $C_{0-6}$alkyl$(SO)C_{1-6}$alkyl$NR^1R^2$, $OC_{1-6}$alkyl$(SO)C_{1-6}$alkyl$NR^1R^2$, $C_{0-6}$alkyl$SC_{1-6}$alkyl$NR^1R^2$, $OC_{1-6}$alkyl$SC_{1-6}$alkyl$NR^1R^2$, $OC_{1-6}$alkyl$OC_{1-6}$alkyl, $C_{1-6}$alkyl$OC_{1-6}$alkyl$NR^1R^2$, $OC_{1-6}$alkyl$OC_{1-6}$alkyl$NR^1R^2$, $C_{0-6}$alkyl$CONR^{10}R^{11}$, $OC_{0-6}$alkyl$CONR^1R^2$, $OC_{1-6}$alkyl$NR^1R^2$, $C_{0-6}$alkyl$NR^{10}(CO)R^{11}$, $OC_{1-6}$alkyl$NR^1(CO)R^2$, $C_{0-6}$alkyl$NR^{11}(CO)R^{10}$, $C_{0-6}$alkyl$COR^{11}$, $OC_{1-6}$alkyl$COR^1$, $C_{0-6}$alkyl$NR^{10}R^{11}$, $C_{0-6}$alkyl$O(CO)R^{11}$, $OC_{1-6}$alkyl$O(CO)R^1$, $C_{0-6}$alkyl$C(NR^{10})NR^{10}R^{11}$,

$C_{0-6}$alkylC($NR^{11}$)N($R^{10}$)$_2$, $OC_{0-6}$alkylC($NR^1$)$NR^1R^2$, $C_{0-6}$alkyl$NR^{10}$(CO)$OR^{11}$, $OC_{1-6}$alkyl$NR^1$(CO)$OR^2$, $C_{0-6}$alkyl$NR^{11}$(CO)$OR^{10}$, $OC_{1-6}$alkylCN, $NR^1OR^2$, $C_{0-6}$alkyl(CO)$OR^8$, $OC_{1-6}$alkyl(CO)$OR^1$, $NR^1$(CO)$NR^1R^2$, $NR^1$(CO)(CO)$R^2$, $NR^1$(CO)(CO)$NR^1R^2$, $OR^{12}$ or $SO_3R^1$;

$R^1$ and $R^2$ are independently selected from hydrogen, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylheterocycloalkyl, $C_{1-6}$alkyl$NR^6R^7$, $C_{0-6}$alkylaryl and $C_{0-6}$alkylheteroaryl, wherein any $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylheterocycloalkyl, $C_{0-6}$alkylaryl, $C_{0-6}$alkylheteroaryl may be substituted by one or more A;

$R^1$ and $R^2$ may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A;

$R^3$ is independently selected from halogen, nitro, CHO, $C_{0-6}$alkylCN, $OC_{1-6}$alkylCN, $C_{0-6}$alkyl$OR^6$, $OC_{1-6}$alkyl$OR^6$, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, $C_{0-6}$alkyl$NR^6R^7$, $OC_{1-6}$alkyl$NR^6R^7$, $OC_{1-6}$alkyl$OC_{1-6}$alkyl$NR^6R^7$, $NR^6OR^7$, $C_{0-6}$alkyl$CO_2R^6$, $OC_{1-6}$alkyl$CO_2R^6$, $C_{0-6}$alkyl$CONR^6R^7$, $OC_{1-6}$alkyl$CONR^6R^7$, $OC_{1-6}$alkyl$NR^6$(CO)$R^7$, $C_{0-6}$alkyl$NR^6$(CO)$R^7$, O(CO)$NR^6R^7$, $NR^6$(CO)$OR^7$, $NR^6$(CO)$NR^6R^7$, O(CO)$OR^6$, O(CO)$R^6$, $C_{0-6}$alkyl$COR^6$, $OC_{1-6}$alkyl$COR^6$, $NR^6$(CO)(CO)$R^6$, $NR^6$(CO)(CO)$NR^6R^7$, $SR^6$, $C_{0-6}$alkyl($SO_2$)$NR^6R^7$, $OC_{1-6}$alkyl$NR^6$($SO_2$)$R^7$, $OC_{0-6}$alkyl($SO_2$)$NR^6R^7$, $C_{0-6}$alkyl(SO)$NR^6R^7$, $OC_{1-6}$alkyl(SO)$NR^6R^7$, $SO_3R^6$, $C_{0-6}$alkyl$NR^6$($SO_2$)$NR^6R^7$, $C_{0-6}$alkyl$NR^6$(SO)$R^7$, $OC_{1-6}$alkyl$NR^6$(SO)$R^7$, $OC_{0-6}$alkyl$SO_2R^6$, $C_{0-6}$alkyl$SO_2R^6$, $C_{0-6}$alkylSO$R^6$, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylaryl and $C_{0-6}$alkylheteroaryl, wherein any $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylaryl and $C_{0-6}$alkylheteroaryl may be optionally substituted by one or more A;

$R^6$ and $R^7$ are independently selected from hydrogen, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylaryl, $C_{0-6}$alkylheteroaryl and $C_{1-6}$alkyl$NR^8R^9$;

$R^6$ and $R^7$ may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S, which heterocyclic ring may be optionally substituted by A and wherein a $CH_2$ group may optionally be replaced by a CO group;

$R^8$ and $R^9$ are independently selected from hydrogen, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylaryl and $C_{0-6}$alkylheteroaryl;
$R^8$ and $R^9$ may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;
$R^{10}$ is hydrogen, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, $C_{0-6}$alkylaryl, $C_{0-6}$alkylheteroaryl or $C_{1-6}$alkyl$NR^8R^9$;
$R^{11}$ is $C_{1-6}$alkyl$NR^8R^9$;
$R^{10}$ and $R^{11}$ may together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which heterocyclic ring may be optionally substituted by A;
A is halogen, oxo (=O), nitro, CHO, CN, $OR^6$, $C_{1-6}$alkyl, $C_{2-6}$alkenyl, $C_{2-6}$alkynyl, $C_{0-6}$alkyl$C_{3-6}$cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, $C_{0-6}$alkyl$NR^6R^7$, $OC_{1-6}$alkyl$NR^6R^7$, $CO_2R^8$, $CONR^6R^7$, $NR^6(CO)R^6$, $O(CO)R^6$, $COR^6$, $SR^6$, $(SO_2)NR^6R^7$, $(SO)NR^6R^7$, $SO_3R^6$, $SO_2R^6$ or $SOR^6$;
m is 0, 1, 2, 3 or 4;
as a free base or a salt, solvate or solvate of a salt thereof.

32. (withdrawn) A compound according to claim 31, wherein:
X is N;
P is phenyl;
R is $C_{0-6}$alkyl$(SO_2)NR^1R^2$;
$R^1$ and $R^2$ may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O or S;
m is 0;
as a free base or a salt, solvate or solvate of a salt thereof.

33. (withdrawn) A compound which is

Methyl 3-{[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate polystyrene;

3-{[2,6-Dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylic acid polystyrene;

as a free base or a salt, solvate or solvate of a salt thereof.

34. (Cancelled).